Early CAR T-cell therapy in relapsed/refractory large B-cell lymphoma is associated with lower hematotoxicity burden
Zeremski V, Aydilek E, Behringer A, Brunner F, Haage TR, Haenel M, Kos I, Krueger W, Lenz G, Lesan V, Schneider J, et al. (2026)
Blood Advances 10(7): 2186-2189.
Zeitschriftenaufsatz
| Veröffentlicht | Englisch
Download
Es wurden keine Dateien hochgeladen. Nur Publikationsnachweis!
Autor*in
Zeremski, Vanja;
Aydilek, EnverUniBi 
;
Behringer, Akhil;
Brunner, Franziska;
Haage, Tobias R.;
Haenel, Mathias;
Kos, Igor;
Krueger, William;
Lenz, Georg;
Lesan, Vadim;
Schneider, Jessica ;
Schultze-Florey, Christian
Alle
;
Behringer, Akhil;
Brunner, Franziska;
Haage, Tobias R.;
Haenel, Mathias;
Kos, Igor;
Krueger, William;
Lenz, Georg;
Lesan, Vadim;
Schneider, Jessica ;
Schultze-Florey, Christian
Alle
Erscheinungsjahr
2026
Zeitschriftentitel
Blood Advances
Band
10
Ausgabe
7
Seite(n)
2186-2189
ISSN
2473-9529
eISSN
2473-9537
Page URI
https://pub.uni-bielefeld.de/record/3016179
Zitieren
Zeremski V, Aydilek E, Behringer A, et al. Early CAR T-cell therapy in relapsed/refractory large B-cell lymphoma is associated with lower hematotoxicity burden. Blood Advances. 2026;10(7):2186-2189.
Zeremski, V., Aydilek, E., Behringer, A., Brunner, F., Haage, T. R., Haenel, M., Kos, I., et al. (2026). Early CAR T-cell therapy in relapsed/refractory large B-cell lymphoma is associated with lower hematotoxicity burden. Blood Advances, 10(7), 2186-2189. https://doi.org/10.1182/bloodadvances.2025018353
Zeremski, Vanja, Aydilek, Enver, Behringer, Akhil, Brunner, Franziska, Haage, Tobias R., Haenel, Mathias, Kos, Igor, et al. 2026. “Early CAR T-cell therapy in relapsed/refractory large B-cell lymphoma is associated with lower hematotoxicity burden”. Blood Advances 10 (7): 2186-2189.
Zeremski, V., Aydilek, E., Behringer, A., Brunner, F., Haage, T. R., Haenel, M., Kos, I., Krueger, W., Lenz, G., Lesan, V., et al. (2026). Early CAR T-cell therapy in relapsed/refractory large B-cell lymphoma is associated with lower hematotoxicity burden. Blood Advances 10, 2186-2189.
Zeremski, V., et al., 2026. Early CAR T-cell therapy in relapsed/refractory large B-cell lymphoma is associated with lower hematotoxicity burden. Blood Advances, 10(7), p 2186-2189.
V. Zeremski, et al., “Early CAR T-cell therapy in relapsed/refractory large B-cell lymphoma is associated with lower hematotoxicity burden”, Blood Advances, vol. 10, 2026, pp. 2186-2189.
Zeremski, V., Aydilek, E., Behringer, A., Brunner, F., Haage, T.R., Haenel, M., Kos, I., Krueger, W., Lenz, G., Lesan, V., Schneider, J., Schultze-Florey, C., Shumilov, E., Weber, T., Wulf, G., Vucinic, V., Mougiakakos, D.: Early CAR T-cell therapy in relapsed/refractory large B-cell lymphoma is associated with lower hematotoxicity burden. Blood Advances. 10, 2186-2189 (2026).
Zeremski, Vanja, Aydilek, Enver, Behringer, Akhil, Brunner, Franziska, Haage, Tobias R., Haenel, Mathias, Kos, Igor, Krueger, William, Lenz, Georg, Lesan, Vadim, Schneider, Jessica, Schultze-Florey, Christian, Shumilov, Evgenii, Weber, Thomas, Wulf, Gerald, Vucinic, Vladan, and Mougiakakos, Dimitrios. “Early CAR T-cell therapy in relapsed/refractory large B-cell lymphoma is associated with lower hematotoxicity burden”. Blood Advances 10.7 (2026): 2186-2189.
Google Scholar